Sirtris causes stir with positive trial data

Sirtris grabbed some headlines at the JP Morgan gathering in San Francisco with its presentation of positive, early-stage data for its closely watched therapy based on resveratrol, an ingredient in red wine that has been linked to increased longevity. In a small diabetes trial the drug delivered positive safety data and demonstrated its ability to cut blood glucose levels. The drug is also in a mid-stage trial in combination with metformin as a therapy for diabetes.

"This is the first time that a small molecule targeting sirtuins, the genes which control the aging process, has shown efficacy in a disease of ageing," said Dr Peter Elliott, senior vice president of development at Sirtris, a 2007 Fierce 15 company. "We are very pleased to see the safety profile observed in preclinical studies translate into a well-tolerated drug molecule in patients, and we are very encouraged by the glucose-lowering effects measured in the oral glucose test."

- check out this release
- read the report on Sirtris in The Telegraph

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.